AXNX
Closed
Axonics Modulation Technologies Inc
70.98
0.00 (0.00%)
Last Update: 15 Nov 2024 17:30:00
Yesterday: 70.98
Day's Range: 70.98 - 70.98
Send
sign up or login to leave a comment!
When Written:
54.56
Axonics Modulation Technologies Inc. is a medical technology company that develops and markets implantable neuromodulation devices for the treatment of urinary and bowel dysfunction. The company was founded in 2013 and is headquartered in Irvine, California.
Axonics' flagship product is the Axonics System, a rechargeable sacral neuromodulation (SNM) device that is designed to treat overactive bladder, urinary retention, and fecal incontinence. The Axonics System is approved by the U.S. Food and Drug Administration (FDA) and has been granted CE mark approval in Europe.
The Axonics System is differentiated from other SNM devices by its long-lived battery, which can last up to 15 years, and its wireless remote control, which allows patients to adjust the stimulation levels of the device. The system is also MRI conditional, meaning that patients can safely undergo magnetic resonance imaging (MRI) scans without the need for device removal or re-implantation.
Axonics has partnerships with leading urologists and academic medical centers to conduct clinical studies and advance the understanding of neuromodulation therapy. The company has also received funding from venture capital firms and strategic investors to support its growth and development.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Axonics' flagship product is the Axonics System, a rechargeable sacral neuromodulation (SNM) device that is designed to treat overactive bladder, urinary retention, and fecal incontinence. The Axonics System is approved by the U.S. Food and Drug Administration (FDA) and has been granted CE mark approval in Europe.
The Axonics System is differentiated from other SNM devices by its long-lived battery, which can last up to 15 years, and its wireless remote control, which allows patients to adjust the stimulation levels of the device. The system is also MRI conditional, meaning that patients can safely undergo magnetic resonance imaging (MRI) scans without the need for device removal or re-implantation.
Axonics has partnerships with leading urologists and academic medical centers to conduct clinical studies and advance the understanding of neuromodulation therapy. The company has also received funding from venture capital firms and strategic investors to support its growth and development.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!